当前位置: 首页 >> 检索结果
7121. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis.
作者: Todd H Baron.;Christopher J DiMaio.;Andrew Y Wang.;Katherine A Morgan.
来源: Gastroenterology. 2020年158卷1期67-75.e1页
The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available evidence and expert recommendations regarding the clinical care of patients with pancreatic necrosis and to offer concise best practice advice for the optimal management of patients with this highly morbid condition.
7123. Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review.
作者: Ilyssa O Gordon.;Dominik Bettenworth.;Arne Bokemeyer.;Amitabh Srivastava.;Christophe Rosty.;Gert de Hertogh.;Marie E Robert.;Mark A Valasek.;Ren Mao.;Satya Kurada.;Noam Harpaz.;Paula Borralho.;Reetesh K Pai.;Rish K Pai.;Robert Odze.;Roger Feakins.;Claire E Parker.;Tran Nguyen.;Vipul Jairath.;Mark E Baker.;David H Bruining.;J G Fletcher.;Brian G Feagan.;Florian Rieder.; .
来源: Gastroenterology. 2020年158卷1期137-150.e1页
Stenosis is a common complication of Crohn's disease (CD) that has no effective medical therapy. Development of antifibrotic agents will require testing in randomized controlled trials. Computed tomography enterography- and magnetic resonance enterography-based technologies might be used to measure outcomes in these trials. These approaches have been validated in studies of patients with symptomatic strictures who underwent imaging evaluations followed by resection with histopathologic grading of the intestinal tissue for inflammation and/or fibrosis (the reference standard). Imaging findings have correlated with findings from quantitative or semiquantitative histologic evaluation of the degree of fibromuscular stenosis and/or inflammation on the resection specimen. However, it is not clear whether histologic findings are an accurate reference standard. We performed a systematic review of all published histologic scoring systems used to assess stenosing CD.
7124. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
作者: Hiroki Oyama.;Minoru Tada.;Kaoru Takagi.;Keisuke Tateishi.;Tsuyoshi Hamada.;Yousuke Nakai.;Ryunosuke Hakuta.;Hideaki Ijichi.;Kazunaga Ishigaki.;Sachiko Kanai.;Hirofumi Kogure.;Suguru Mizuno.;Kei Saito.;Tomotaka Saito.;Tatsuya Sato.;Tatsunori Suzuki.;Naminatsu Takahara.;Yasuyuki Morishita.;Junichi Arita.;Kiyoshi Hasegawa.;Mariko Tanaka.;Masashi Fukayama.;Kazuhiko Koike.
来源: Gastroenterology. 2020年158卷1期226-237.e5页
Long-term outcomes of patients with branch-duct intraductal papillary mucinous neoplasms (IPMNs), particularly those after 5 years of surveillance, have not been fully evaluated in large studies. We analyzed incidences of IPMN-derived carcinoma and concomitant ductal adenocarcinoma (pancreatic ductal adenocarcinoma [PDAC]) over 20 years in a large population of patients.
7126. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
作者: Zsa Zsa R M Weerts.;Ad A M Masclee.;Ben J M Witteman.;Cees H M Clemens.;Bjorn Winkens.;Jacobus R B J Brouwers.;Henderik W Frijlink.;Jean W M Muris.;Niek J De Wit.;Brigitte A B Essers.;Jan Tack.;Johanna T W Snijkers.;Andrea M H Bours.;Annieke S de Ruiter-van der Ploeg.;Daisy M A E Jonkers.;Daniel Keszthelyi.
来源: Gastroenterology. 2020年158卷1期123-136页
Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of evidence for efficacy from high-quality controlled trials. We studied the efficacy and safety of small-intestinal-release peppermint oil in patients with IBS and explored the effects of targeted ileocolonic-release peppermint oil.
7127. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
作者: William J Sandborn.;Filip Baert.;Silvio Danese.;Željko Krznarić.;Taku Kobayashi.;Xiaopan Yao.;Jingjing Chen.;Maria Rosario.;Siddharth Bhatia.;Krisztina Kisfalvi.;Geert D'Haens.;Séverine Vermeire.
来源: Gastroenterology. 2020年158卷3期562-572.e12页
Maintenance treatment with vedolizumab, a monoclonal antibody that inhibits the gut-selective α4β7 integrin, is administered intravenously. Some patients might prefer a subcutaneous formulation of vedolizumab for maintenance treatment. Subcutaneous vedolizumab was investigated as maintenance treatment in patients with moderately to severely active ulcerative colitis.
7128. Transgenic Expression of PRSS1R122H Sensitizes Mice to Pancreatitis.
作者: Haojie Huang.;Agnieszka Katarzyna Swidnicka-Siergiejko.;Jaroslaw Daniluk.;Sebastian Gaiser.;Yao Yao.;Lisi Peng.;Yang Zhang.;Yan Liu.;Minyu Dong.;Xianbao Zhan.;Huamin Wang.;Yan Bi.;Zhaoshen Li.;Baoan Ji.;Craig D Logsdon.
来源: Gastroenterology. 2020年158卷4期1072-1082.e7页
Mutations in the trypsinogen gene (PRSS1) cause human hereditary pancreatitis. However, it is not clear how mutant forms of PRSS1 contribute to disease development. We studied the effects of expressing mutant forms of human PRSS1 in mice.
7133. Strategies for Colorectal Cancer Screening.
作者: Uri Ladabaum.;Jason A Dominitz.;Charles Kahi.;Robert E Schoen.
来源: Gastroenterology. 2020年158卷2期418-432页
The incidence of colorectal cancer (CRC) is increasing worldwide. CRC has high mortality when detected at advanced stages, yet it is also highly preventable. Given the difficulties in implementing major lifestyle changes or widespread primary prevention strategies to decrease CRC risk, screening is the most powerful public health tool to reduce mortality. Screening methods are effective but have limitations. Furthermore, many screen-eligible people remain unscreened. We discuss established and emerging screening methods, and potential strategies to address current limitations in CRC screening. A quantum step in CRC prevention might come with the development of new screening strategies, but great gains can be made by deploying the available CRC screening modalities in ways that optimize outcomes while making judicious use of resources.
7134. Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults.
In contrast to the decreasing incidence of colorectal cancer (CRC) in older populations, the incidence has nearly doubled in younger adults since the early 1990s. Approximately 1 in 10 new diagnoses of CRC are now made in individuals 50 years or younger. Patients' risk of CRC has been calculated largely by age and family history, yet 3 of 4 patients with early-onset CRC have no family history of the disease. Rapidly increasing incidence rates in younger people could result from generational differences in diet, environmental exposures, and lifestyle factors. We review epidemiologic trends in CRC, data on genetic and nongenetic risk factors, and new approaches for determining CRC risk. These may identify individuals likely to benefit from early screening and specialized surveillance.
7140. Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance.
作者: David Lieberman.;Brian A Sullivan.;Elizabeth R Hauser.;Xuejun Qin.;Laura W Musselwhite.;Meghan C O'Leary.;Thomas S Redding.;Ashton N Madison.;A Jasmine Bullard.;Reana Thomas.;Kellie J Sims.;Christina D Williams.;Terry Hyslop.;David Weiss.;Samir Gupta.;Ziad F Gellad.;Douglas J Robertson.;Dawn Provenzale.
来源: Gastroenterology. 2020年158卷4期862-874.e8页
Few studies have evaluated long-term outcomes of ongoing colonoscopic screening and surveillance in a screening population. We aimed to determine the 10-year risk for advanced neoplasia (defined as adenomas ≥10mm, adenomas with villous histology or high-grade dysplasia, or colorectal cancer [CRC]) and assessed whether baseline colonoscopy findings were associated with long-term outcomes.
|